Northern Trust Corp Grows Position in Enzo Biochem, Inc. (ENZ)

Northern Trust Corp lifted its holdings in Enzo Biochem, Inc. (NYSE:ENZ) by 8.8% during the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 506,879 shares of the medical research company’s stock after acquiring an additional 40,939 shares during the period. Northern Trust Corp owned approximately 1.09% of Enzo Biochem worth $5,596,000 as of its most recent filing with the SEC.

Several other hedge funds have also added to or reduced their stakes in ENZ. Bank of New York Mellon Corp grew its stake in shares of Enzo Biochem by 1.2% in the first quarter. Bank of New York Mellon Corp now owns 206,447 shares of the medical research company’s stock valued at $1,728,000 after acquiring an additional 2,409 shares in the last quarter. JPMorgan Chase & Co. acquired a new position in shares of Enzo Biochem in the first quarter valued at about $220,000. American International Group Inc. grew its stake in shares of Enzo Biochem by 7.1% in the first quarter. American International Group Inc. now owns 24,432 shares of the medical research company’s stock valued at $204,000 after acquiring an additional 1,610 shares in the last quarter. Teachers Advisors LLC grew its stake in shares of Enzo Biochem by 25.6% in the first quarter. Teachers Advisors LLC now owns 140,745 shares of the medical research company’s stock valued at $1,178,000 after acquiring an additional 28,722 shares in the last quarter. Finally, TIAA CREF Investment Management LLC grew its stake in shares of Enzo Biochem by 17.9% in the first quarter. TIAA CREF Investment Management LLC now owns 371,069 shares of the medical research company’s stock valued at $3,106,000 after acquiring an additional 56,301 shares in the last quarter. Institutional investors and hedge funds own 62.46% of the company’s stock.

Shares of Enzo Biochem, Inc. (NYSE:ENZ) opened at $9.20 on Thursday. Enzo Biochem, Inc. has a one year low of $6.27 and a one year high of $12.04.

ENZ has been the topic of several research reports. BidaskClub downgraded shares of Enzo Biochem from a “hold” rating to a “sell” rating in a research note on Monday, August 14th. Zacks Investment Research downgraded shares of Enzo Biochem from a “buy” rating to a “hold” rating in a research note on Tuesday, August 15th. Finally, TheStreet downgraded shares of Enzo Biochem from a “b” rating to a “c+” rating in a research note on Wednesday, September 27th.

In other Enzo Biochem news, Director Gregory M. Bortz sold 42,005 shares of the stock in a transaction dated Tuesday, October 31st. The shares were sold at an average price of $9.82, for a total transaction of $412,489.10. Following the sale, the director now directly owns 292,875 shares in the company, valued at $2,876,032.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, EVP James Michael O’brien sold 22,866 shares of the stock in a transaction dated Friday, October 27th. The stock was sold at an average price of $10.28, for a total transaction of $235,062.48. Following the sale, the executive vice president now owns 34,886 shares in the company, valued at $358,628.08. The disclosure for this sale can be found here. Insiders have sold 191,398 shares of company stock worth $1,925,292 over the last quarter. Corporate insiders own 9.50% of the company’s stock.

WARNING: This piece of content was originally published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of United States and international copyright laws. The original version of this piece of content can be read at https://ledgergazette.com/2017/11/16/northern-trust-corp-grows-position-in-enzo-biochem-inc-enz.html.

About Enzo Biochem

Enzo Biochem, Inc is a bioscience company focusing on delivering and applying technology capabilities to produce products and services. The Company’s segments include Enzo Clinical Labs, Enzo Life Sciences and Enzo Therapeutics. Enzo Clinical Labs is a clinical reference laboratory providing a range of clinical services to physicians, medical centers, other clinical labs and pharmaceutical companies.

Institutional Ownership by Quarter for Enzo Biochem (NYSE:ENZ)

Receive News & Ratings for Enzo Biochem Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzo Biochem Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply